Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0.

Aeolus Pharmaceuticals second quarter 2010 net loss increases to $0 .10 per share Aeolus Pharmaceuticals, Inc. announced today monetary results for the three months ended June 30, 2010. The Company reported a net loss of $4,623,000, or $0.10 per share, in comparison to a net loss of $426,000, or $0.01 per talk about, for the 90 days ended June 30, 2009. The 3rd quarter 2010 results include a noncash financing and modification in valuation charge of $3,856,000. Reduction from procedures for the three months ended June 30, 2010 were $750,000 compared to $445,june 30 000 for the 90 days ended, 2009. McManus, President and Chief Executive Officer. ‘We have successfully leveraged the financing and support our analysis collaborators receive from the NIH CounterACT and NIH-NIAID programs in addition to patient advocacy groups like the Michael J Fox Basis to establish eight research applications which address a range of unmet medical desires.’ Related StoriesNew tool may help diagnose and treat Parkinson's disease in early stagesStudy shows antipsychotic medication increases loss of life risk in patients with Parkinson's disease psychosisLewy Body Composite Risk Rating detects LBD and Parkinson's disease dementia in 3 minutesResearch and development expenses increased about $145,000 for the three months ended June 30, 2010 due to a rise in Lung ARS related analysis activities.

Bill Adolescent Cell Transplantation System and the National Cord Blood Inventory, Increase Financing to Expand the Nation’s Marrow and Cord Bloodstream Registry to meet up Americans’ Increased Dependence on Transplant More than 60 adult donors, transplant recipients, family members and medical professionals from 25 states met with lawmakers and personnel on Capitol Hill today to desire Congress for elevated federal funding to grow and diversify the national registry of adult donors and publicly available cord blood units within the C.W. Costs Young Transplantation Program and the National Cord Blood Inventory . ‘With increasing numbers of Americans in need of bone marrow and cord blood transplants each year, reauthorization of the Program and the NCBI and additional funding for the Program, are critical to expand usage of transplant for all Americans,’ said Jeffrey W.